Export 7 results:
Filters: Author is Korbling,M. [Clear All Filters]
Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: No evidence of increased risk of leukemia development. Bone Marrow Transplant. 2002;30:661-663.
Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. Journal of Clinical Apheresis. 2001;16(2):82-7.
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.[Erratum appears in Transfusion 1997 Jan;37(1):109]. Transfusion. 1996;36(7):590-5.
Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplantation. 1996;18(6):1073-9.
Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. British Journal of Haematology. 1996;94(1):155-8.